10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Mouse Fgfr3 Antibody (Center)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP14841c

Product Information

Application	WB, IHC-P, E
Primary Accession	Q61851
Reactivity	Human, Mouse
Predicted	Rat, Bovine, Canine
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB34774
Calculated MW	87758
Antigen Region	468-495

Additional Information

Other Names	Fibroblast growth factor receptor 3, FGFR-3, Heparin-binding growth factor receptor, CD333, Fgfr3, Mfr3, Sam3
Target/Specificity	This Mouse Fgfr3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 468-495 amino acids from the Central region of mouse Fgfr3.
Dilution	WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Mouse Fgfr3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	Fgfr3
Synonyms	Mfr3, Sam3
Function	Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the

regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of STAT1, STAT5A and STAT5B. Plays a role in postnatal lung development.

Cellular Location

Cell membrane; Single-pass type I membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum. Note=The activated receptor is rapidly internalized and degraded. Detected in intracellular vesicles after internalization of the autophosphorylated receptor (By similarity).


Tissue Location

In embryo, expressed in heart, lung, kidney, skin, head and liver but not in muscle. In adult, highest levels in brain Also expressed in liver, lung, kidney, testis, ovary and uterus. Very low levels in heart, thymus, spleen and muscle


Background

Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.

Images



Mouse Fgfr3 Antibody (Center) (Cat. #AP14841c) western blot analysis in 293 cell line lysates (35ug/lane).This demonstrates the Fgfr3 antibody detected the Fgfr3 protein (arrow).



VN1R1 Antibody (N-term) (AP14841c)immunohistochemistry analysis in formalin fixed and paraffin embedded mouse brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of VN1R1 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

Citations

- FGFR mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.